Inventor · disambiguated record
Koustubh Ranade
Also filed as: RANADE KOUSTUBH
13 granted patents·20 pending applications·7 citations·filing 2004–2023
85Inventor score
Top patents by PatentIndex Score
33 records- 0181US11016099B2Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkersAMGEN INC·Filed 2016·Granted May 25, 2021·3 cites·22 claims
- 0279US9932637B2Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereofCELERA CORP·Filed 2016·Granted Apr 3, 2018·2 cites·25 claims
- 0377US11220541B2CCL20 as a predictor of clinical response to IL23-antagonistsAMGEN INC·Filed 2016·Granted Jan 11, 2022·1 cites·32 claims
- 0474US11708610B2Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereofCELERA CORP·Filed 2021·Granted Jul 25, 2023·0 cites·14 claims
- 0570US10775388B2Methods of using antibodies to determine periostin levels in a sampleMEDIMMUNE LLC·Filed 2015·Granted Sep 15, 2020·1 cites·23 claims
- 0669US2023145764A1Blood-based tumor mutation burden predicts overall survival in nsclcMEDIMMUNE LLC·Filed 2022·Application pending·0 cites
- 0765US10982281B2Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereofCELERA CORP·Filed 2018·Granted Apr 20, 2021·0 cites·18 claims
- 0864US2023303707A1Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritisMEDIMMUNE LTD·Filed 2023·Application pending·0 cites
- 0963US2022144935A1Ccl20 as a predictor of clinical response to il23-antagonistsAMGEN INC·Filed 2021·Application pending·0 cites
- 1063US2020190598A1Blood-based tumor mutation burden predicts overall survival in nsclcMEDIMMUNE LLC·Filed 2019·Application pending·0 cites
- 1162US7598029B2Method for identifying HIV-1 protease inhibitors with reduced metabolic affectsBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Oct 6, 2009·0 cites·8 claims
- 1260US2014221484A1Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 1357US7642049B2Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphismsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Jan 5, 2010·0 cites·8 claims
- 1457US2005272054A1Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereofAPPLERA CORP·Filed 2004·Application pending·0 cites
- 1556US11613580B2Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritisMEDIMMUNE LTD·Filed 2017·Granted Mar 28, 2023·0 cites·11 claims
- 1655US9862762B2Monoclonal antibodies which bind human periostinMEDIMMUNE LLC·Filed 2015·Granted Jan 9, 2018·0 cites·18 claims
- 1755US7329490B2Methods for diagnosing schizophrenia by detecting a polymorphism in the KalphaM1 geneBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Feb 12, 2008·0 cites·6 claims
- 1855US2018179272A1Novel assay to detect human periostinMEDIMMUNE LLC·Filed 2017·Application pending·0 cites
- 1953US2022373539A1Prediction of clinical response to il23-antagonists using il23 pathway biomarkersAMGEN INC·Filed 2021·Application pending·0 cites
- 2053US2009202994A1Human single nucleotide polymorphisms in ion channels and other proteinsBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 2152US10006026B2Recombinant polypeptide productionMEDIMMUNE LLC·Filed 2014·Granted Jun 26, 2018·0 cites·20 claims
- 2252US2010190172A1Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereofCELERA CORP·Filed 2010·Application pending·0 cites
- 2350US2007190539A1Human MLR single nucleotide polymorphisms associated with dose-dependent congestive heart failure and methods of use thereofBRISTOL MYERS SQUIBB CO·Filed 2006·Application pending·0 cites
- 2450US2007202512A1Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereofBRISTOL MYERS SQUIBB CO·Filed 2006·Application pending·0 cites
- 2548US2015252431A1Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapyMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
- 2648US2017088628A1Compositions and Methods for Identifying B Cell Malignancies Responsive to B Cell Depleting TherapyMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 2745US2005014177A1Human sterol response element binding protein 1 (SREBP1) single nucleotide polymorphismsFiled 2004·Application pending·0 cites
- 2842US7482124B2Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edemaBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jan 27, 2009·0 cites·17 claims
- 2941US2018282417A1Tumor burden as measured by cell free dnaMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 3041US2011152340A1Methods for Identifying Subjects With an Increased Likelihood of Responding to DPP-IV InhibitorsBRISTOL MYERS SQUIBB CO·Filed 2009·Application pending·0 cites
- 3138US2013108646A1Optimized degenerative muscle disease diagnostics and treatmentsYAO YIHONG·Filed 2011·Application pending·0 cites
- 3236US2014045924A1Melanoma treatmentsYAO YIHONG·Filed 2011·Application pending·0 cites
- 3331US2016363591A1Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lungMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Koustubh Ranade files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →